SARAH CASTILLO: Open Payments
NPI 1700141850 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$555 in 33 payments from 11 companies in 2025. Trend: 2023 $125 · 2024 $191 · 2025 $555
Food & beverage: $555
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $305 |
| Novartis Pharmaceuticals Corporation | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Novo Nordisk Inc | 2 | $32 |
| PFIZER INC. | 2 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Organon LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
| Amgen Inc. | 1 | $14 |
Products named: VRAYLAR, QULIPTA, LEQVIO, REXULTI, Ozempic, PREVNAR 20, LINZESS, UBRELVY.
Industry payments across NE — which companies pay providers there.
